Pooled prevalence rates of developing thromboembolic and/or pregnancy events and related deaths in patients with solid tumors (n = 10 studies)
| Cancer type (no. of studies) . | No. of positive patients . | Total no. of patients . | Pooled prevalence* (95% CI), % . |
|---|---|---|---|
| Thromboembolic/pregnancy events in patients with solid tumors (as reported in the entire sample) | |||
| Lung (n = 2)24,45,53 | 72 | 314 | 23 (18-28) |
| GU (n = 4)43,51,55,56 | 62 | 293 | 19 (12-28) |
| Bone/soft tissue (n = 1)23 | 19 | 122 | 16 (10-23) |
| Unspecified solid tumor (n = 3)49,50,60,61 | 44 | 232 | 22 (7-41) |
| Thromboembolic/pregnancy events in patients with solid tumors who have positive aPL antibodies | |||
| Lung (n = 2)24,45,53 | 51 | 147 | 35 (27-43%) |
| GU (n = 2)43,56 | 10 | 40 | 21 (8-38) |
| Death due to thromboembolic events in patients with solid tumors who have positive aPL antibodies | |||
| Lung (n = 1)53 | 36 | 84 | 43 (33-54) |
| Bone/soft tissue (n = 1)23 | 1 | 4 | 25 (5-70) |
| Cancer type (no. of studies) . | No. of positive patients . | Total no. of patients . | Pooled prevalence* (95% CI), % . |
|---|---|---|---|
| Thromboembolic/pregnancy events in patients with solid tumors (as reported in the entire sample) | |||
| Lung (n = 2)24,45,53 | 72 | 314 | 23 (18-28) |
| GU (n = 4)43,51,55,56 | 62 | 293 | 19 (12-28) |
| Bone/soft tissue (n = 1)23 | 19 | 122 | 16 (10-23) |
| Unspecified solid tumor (n = 3)49,50,60,61 | 44 | 232 | 22 (7-41) |
| Thromboembolic/pregnancy events in patients with solid tumors who have positive aPL antibodies | |||
| Lung (n = 2)24,45,53 | 51 | 147 | 35 (27-43%) |
| GU (n = 2)43,56 | 10 | 40 | 21 (8-38) |
| Death due to thromboembolic events in patients with solid tumors who have positive aPL antibodies | |||
| Lung (n = 1)53 | 36 | 84 | 43 (33-54) |
| Bone/soft tissue (n = 1)23 | 1 | 4 | 25 (5-70) |
Pooled prevalence is weighted by study size.